Intas B2B Dossier e-portfolio

Published by: INTAS Pharmaceuticals
Downloads
Revenue

Description

Access to Intas B2B portfolio Global-Dossiers: Biosimilars, Added Value Medicines and Generics.
Access to visual overviews on regulatory information and launch landscape.
Search through our portfolio using filters as stability clime zone, jurisdiction, therapeutic area and more.
Always updated with our last developments, filing plan and available MAs.
Hide Show More...

Screenshots

Intas B2B Dossier e FAQ

  • Is Intas B2B Dossier e free?

    Yes, Intas B2B Dossier e is completely free and it doesn't have any in-app purchases or subscriptions.

  • Is Intas B2B Dossier e legit?

    Not enough reviews to make a reliable assessment. The app needs more user feedback.

    Thanks for the vote

  • How much does Intas B2B Dossier e cost?

    Intas B2B Dossier e is free.

  • What is Intas B2B Dossier e revenue?

    To get estimated revenue of Intas B2B Dossier e app and other AppStore insights you can sign up to AppTail Mobile Analytics Platform.

User Rating
App is not rated in United Kingdom yet.
Ratings History

Intas B2B Dossier e Reviews

No Reviews in United Kingdom
App doesn't have any reviews in United Kingdom yet.

Store Rankings

Ranking History
App Ranking History not available yet
Category Rankings
App is not ranked yet

Intas B2B Dossier e Competitors

Name
Walkon-Virtual Unity Walkathon
N/A
eVitalPlus - For Doctor
Cipla Gx
Retailio Salesman Partner
Supplier's marketplace
AgeeHealth
Laxmi Healthcare
DrPerfect

Intas B2B Dossier e Installs

Last 30 days

Intas B2B Dossier e Revenue

Last 30 days

Intas B2B Dossier e Revenue and Downloads

Gain valuable insights into Intas B2B Dossier e performance with our analytics.
Sign up now to access downloads, revenue, and more.
This page includes copyrighted content from third parties, shared solely for commentary and research in accordance with fair use under applicable copyright laws. All trademarks, including product, service, and company names or logos, remain the property of their respective owners. Their use here falls under nominative fair use as outlined by trademark laws and does not suggest any affiliation with or endorsement by the trademark holders.